Want to see DE:HPHA full AI Analyst Report?
HPHA Stock Chart & Stats
€2.40
€0.02(0.83%)
At close: 4:00 PM EST
€2.40
€0.02(0.83%)
Day’s Range― - ―
52-Week Range€2.33 - €4.64
Previous CloseN/A
Volume3.96K
Average Volume (3M)8.49K
Market Cap
€117.90M
Enterprise Value€152.89
Total Cash (Recent Filing)€24.93M
Total Debt (Recent Filing)€45.98K
Price to Earnings (P/E)―
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,784,317
10 Day Avg. Volume3,574
30 Day Avg. Volume8,494
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-12.31
Price to Sales (P/S)92.22
P/FCF Ratio-4.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong TTM revenue rebound indicates improved activity across collaborations or development programs. Sustaining this growth could expand the company’s funding base and increase the commercial relevance of its pipeline, although profitability remains unproven.
Proprietary ADC PlatformA proprietary targeted-delivery platform gives Heidelberg Pharma a defined technological focus in oncology. If its ATAC approach translates into clinical and partnering success, the platform could support multiple candidates and recurring licensing opportunities.
Minimal DebtMinimal stated debt limits conventional interest and repayment burdens, preserving some operational flexibility while the pipeline develops. This benefit is moderated by negative equity and ongoing cash burn, but the company is not primarily constrained by high debt leverage.
Bears Say
Persistent Net LossesLarge recurring losses show that current revenue is insufficient to cover operating expenses. Without meaningful margin improvement or successful partnering income, continued development will remain dependent on external funding and could pressure shareholder returns.
Sustained Cash BurnPersistent negative operating and free cash flow indicate that the business does not yet finance itself. Continued cash consumption can force new capital raises, asset disposals, or development prioritization, creating execution and dilution risks over the medium term.
Negative Shareholders’ EquityNegative equity reflects cumulative losses that have eroded the capital base and reduces financial resilience. It can restrict funding flexibility and increase dependence on investors or strategic partners to sustain clinical development and corporate operations.
HPHA FAQ
What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest stock price was €2.33 and its highest was €4.64 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €117.90M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Heidelberg Pharma AG’s earnings last quarter?
Currently, no data Available
Is Heidelberg Pharma AG overvalued?
According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,784,317 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in DE:HPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heidelberg Pharma AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.91%
Trailing 12-Months
Company Description
Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Technical Analysis
―
B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Formycon AG
―